

Background **Importance** 

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is a major cause of morbidity and mortality globally

35% to 65%

NSCLC patients

Present nutritional such as malnutrition or sarcopenia (characterized by the loss of skeletal muscle mass and strength)




Important negative impacts

Treatment response

Prognosis Quality of life

Identifying the nutritional status and body composition of patients receiving targeted therapies like osimertinib is essential to optimize treatment and manage adverse effects

**Objetives** 





## **Materials and Methods**

Study the nutritional status and body composition of NSCLC patients with osimertinib


Evaluate the prevalence of sarcopenia and examine the relationship between low muscle mass, malnutrition and the occurrence of dose-limiting toxicities

Observational, descriptive, cross-sectional treated with osimertinib

**Analize** 


Body composition

Bioelectrical impedance (BIA)




functionality

**Dynamometry** 



Weight, height, IMC, ...





## Conclusions

These findings emphasize the importance of early and individualized nutritional interventions in NSCLC patients receiving osimertinib to enhance their nutritional status, optimize cancer treatment, and reduce dose-limiting toxicities. Future research involving larger patient cohorts and longitudinal designs is needed to validate these results and investigate the efficacy of nutritional interventions.

